Quality of life study for relapsed myeloma immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with multiple myeloma.
- Your myeloma has come back or is not responding to treatment.
- You have already been treated with at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody.
- You are scheduled to start a new immunotherapy within one month of screening.
- You agree to take part after learning about the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study tests a two-step approach for people with relapsed or hard-to-treat multiple myeloma. First, you get a bispecific antibody (a drug that helps your immune system attack myeloma cells), then you receive CAR-T cell therapy (your own immune cells modified to fight the cancer). The goal is to see if this combination works well together.
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
Hear when a new Multiple Myeloma, Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.